N-terminal pro-B-type natriuretic peptide and the risk of stroke and transient ischaemic attack: The Rotterdam Study

European Journal of Neurology

Volumn 22, Issue 4, 2015, Pages 695-701

  Portegies, M L P ^a   Kavousi, M ^a   Leening, M J G ^a   Bos, M J ^a   van den Meiracker, A H ^a   Hofman, A ^a   Franco, O H ^a   Koudstaal, P J ^a   Ikram, M A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Epidemiology; NT proBNP; Risk factors; Stroke; Transient ischaemic attack

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX; TRANSIENT ISCHEMIC ATTACK; BLOOD; CEREBROVASCULAR DISEASE; COMPLICATION; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; NETHERLANDS; RISK FACTOR; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CEREBROVASCULAR DISORDERS; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NETHERLANDS; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84924453322     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12633     Document Type: Article

References (27)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-328.
2. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-322.
3. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616.
4. Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 2012; 156: 438-444.
5. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
6. Rutten JH, Mattace-Raso FU, Steyerberg EW, et al. Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam Study. Hypertension 2010; 55: 785-791.
7. Folsom AR, Nambi V, Bell EJ, et al. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the Atherosclerosis Risk in Communities Study. Stroke 2013; 44: 961-967.
8. Takahashi T, Nakamura M, Onoda T, et al. Predictive value of plasma B-type natriuretic peptide for ischemic stroke: a community-based longitudinal study. Atherosclerosis 2009; 207: 298-303.
9. Doi Y, Ninomiya T, Hata J, et al. N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in a Japanese community: the Hisayama study. Arterioscler Thromb Vasc Biol 2011; 31: 2997-3003.
10. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663.
11. Dutta M, Hanna E, Das P, Steinhubl SR. Incidence and prevention of ischemic stroke following myocardial infarction: review of current literature. Cerebrovasc Dis 2006; 22: 331-339.
12. Ferro JM. Cardioembolic stroke: an update. Lancet Neurol 2003; 2: 177-188.
13. Alberts VP, Bos MJ, Koudstaal P, et al. Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol 2010; 25: 807-812.
14. de Lau LM, den Hertog HM, van den Herik EG, Koudstaal PJ. Predicting and preventing stroke after transient ischemic attack. Expert Rev Neurother 2009; 9: 1159-1170.
15. Lenzen MJ, Rosengren A, Scholte op Reimer WJ, et al. Management of patients with heart failure in clinical practice: differences between men and women. Heart 2008; 94: e10.
16. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 2011; 124: 2145-2154.
17. Hofman A, Darwish Murad S, van Duijn CM, et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol 2013; 28: 889-926.
18. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006; 27: 330-337.
19. Yeo KT, Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003; 338: 107-115.
20. Leening MJ, Kavousi M, Heeringa J, et al. Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol 2012; 27: 173-185.
21. Wieberdink RG, Ikram MA, Hofman A, Koudstaal PJ, Breteler MM. Trends in stroke incidence rates and stroke risk factors in Rotterdam, the Netherlands, from 1990 to 2008. Eur J Epidemiol 2012; 27: 287-295.
22. Bos MJ, van Rijn MJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Incidence and prognosis of transient neurological attacks. JAMA 2007; 298: 2877-2885.
23. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990; 21: 637-676.
24. Wachter R, Lahno R, Haase B, et al. Natriuretic peptides for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemia - the Find-AF study. PLoS ONE 2012; 7: e34351.
25. Kardys I, Vliegenthart R, Oudkerk M, Hofman A, Witteman JC. The female advantage in cardiovascular disease: do vascular beds contribute equally? Am J Epidemiol 2007; 166: 403-412.
26. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
27. Gerber IL, Stewart RA, Legget ME, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003; 107: 1884-1890.